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Central Sympatholysis as a Novel
Countermeasure for Cocaine-Induced
Sympathetic Activation and Vasoconstriction in Humans
Dileep V. Menon, MD, Zhongyun Wang, MD, Paul J. Fadel, PHD, Debbie Arbique, RN,
David Leonard, PHD, Jia-Ling Li, MD, Ronald G. Victor, MD, FACC,
Wanpen Vongpatanasin, MD, FACC
Dallas, Texas
Objectives The aim of this study was to determine whether cocaine’s sympathomimetic actions can be reversed by a potent
centrally acting 2 adrenergic receptor (AR) agonist (dexmedetomidine).
Background We recently showed that cocaine stimulates the human cardiovascular system primarily by acting in the brain to
increase sympathetic nerve activity (SNA), the neural stimulus to norepinephrine release. Thus, SNA constitutes
a putative new drug target to block cocaine’s adverse cardiovascular effects at their origin.
Methods In 22 healthy cocaine-naïve humans, we measured skin SNA (microneurography) and skin blood flow (laser
Doppler velocimetry) as well as heart rate and blood pressure before and after intranasal cocaine (2 mg/kg)
alone and in combination with dexmedetomidine or saline.
Results During intranasal cocaine alone, SNA increased by 2-fold and skin vascular resistance increased from 13.2 
2.3 to 20.1  2.2 resistance units while mean arterial pressure increased by 14  3 mm Hg and heart rate by
18  3 beats/min (p  0.01). Dexmedetomidine abolished these increases, whereas intravenous saline was
without effect. Dexmedetomidine was effective in blocking these sympathomimetic actions of cocaine even in
all 7 subjects who were homozygous for the Del322-325 polymorphism in the 2C AR, a loss-of-function muta-
tion that is highly enriched in blacks.
Conclusions The data advance the novel hypothesis that central sympatholysis with dexmedetomidine constitutes a highly
effective countermeasure for cocaine’s sympathomimetic actions on the human cardiovascular system, even
in individuals carrying the 2CDel322-325 polymorphism. (Study to Improve Scientific Understanding
of the Cardiovascular Actions of Cocaine; http://clinicaltrials.gov/ct/show/NCT00338546?order1;
NCT00338546) (J Am Coll Cardiol 2007;50:626–33) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.060g
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socaine abuse has reached epidemic proportions in the U.S.,
ith 34.9 million Americans reporting having ever tried
ocaine and an estimated 7.3 million regular users, including
5% of young adults ages 18 to 25 years (1). Cocaine is the
ominant illicit drug causing life-threatening cardiovascular
mergencies. These include acute coronary syndromes, sudden
ardiac death, malignant hyperthermia, and hypertensive crisis
ncluding stroke and aortic dissection. Although these emer-
rom the Hypertension Division and the Donald W. Reynolds Cardiovascular
linical Research Center, University of Texas Southwestern Medical Center, Dallas,
exas. This work was supported by grants to Dr. Victor from the National Institute on
rug Abuse (RO-1 DA10064) and the American Society of Hypertension (Texas
hapter) and to Drs. Vongpatanasin and Victor from the Donald W. Reynolds
oundation.o
Manuscript received December 12, 2006; revised manuscript received March 14,
007, accepted March 28, 2007.encies all are related to excessive adrenergic stimulation of the
ardiovascular system, our understanding of the underlying
echanisms mediating cocaine’s sympathomimetic effects is
ar from complete and current strategies for emergency man-
gement remain unsatisfactory.
The standard theory is that cocaine blocks norepineph-
ine (NE) reuptake in peripheral sympathetic nerve termi-
als, thereby increasing NE in the synaptic cleft (2). In
ontrast to this rather traditional view, our recent studies
emonstrate that cocaine stimulates the human cardiovas-
ular system primarily by acting in the brain to increase
entral sympathetic nerve activity (SNA) (3), the neural
timulus to NE release, with minimal contribution from
eripheral NE transporter inhibition (4). Thus, SNA con-
titutes a putative new drug target for the acute management
f cocaine-induced cardiovascular emergencies.
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August 14, 2007:626–33 Cocaine and DexmedetomidineCentral sympatholytic drugs, particularly -adrenergic
eceptor (AR) agonists such as clonidine, have been shown
o reverse cocaine-induced increases in blood pressure and
ascular resistance in experimental animals (5). Dexmedeto-
idine is a newer central sympatholytic agent with an 2
R binding affinity that is 8 times higher than that for
lonidine (6,7). This 2 AR agonist is increasingly used as
n anesthetic agent and has proven to be particularly
ffective in minimizing acute hypertension and tachycardia
n surgical and critically ill patients (8,9). Dexmedetomidine
as been shown to markedly attenuate cocaine-induced
oronary and systemic vasoconstriction in dogs (10), but
ranslational human studies previously have not been
eported.
Accordingly, the goal of the present study was to test
hether controlling cocaine-induced central sympathetic
ctivation with dexmedetomidine can effectively reverse the
cute hemodynamic responses to cocaine. Here we con-
ucted a prospective randomized placebo-controlled study
n cocaine-naïve healthy subjects in whom we performed
icroelectrode recordings of skin SNA, a regional sympa-
hetic outflow that is highly reactive to low-dose intranasal
ocaine (3), and simultaneously measured skin vascular
esistance as the primary hemodynamic end point. We
itrated the dexmedetomidine dose to eliminate the cocaine-
nduced increase in skin SNA and determined whether this
ntervention would be sufficient to completely reverse the
ttendant increases in skin vascular resistance as well as in
eart rate and blood pressure. To address applicability of the
ndings in broader ethnic population, we enriched the study
amples with subjects who are homozygous for a loss-of-
unction mutation in the 2C AR (2CDel322-325), a
arget of dexdemetomidine. This mutation occurs mainly in
lacks (11), the population with the highest cardiovascular
ortality in the U.S. (12).
ethods
e studied 22 healthy volunteers (9 men and 13 women, 21
o 56 years of age) after obtaining informed written consent.
he protocol was approved by the Institutional Review
oard of The University of Texas Southwestern Medical
enter. All subjects were normotensive and had no history
f cardiovascular disease, cocaine abuse, or other recre-
tional drug abuse. None of the subjects was taking any
rescription or nonprescription drugs with cardiovascular or
utonomic effects.
All experiments were performed under normothermic
onditions (22°C) with the subjects supine. Blood pressure
as measured by the oscillometric technique with the
italsigns Monitor (CE00050, Welch Allyn, Tycos Instru-
ents, Inc., Skaneateles Falls, New York). Heart rate was
onitored continuously by a cardiotachometer triggered by
wave of an electrocardiogram lead. Respiratory rate was
onitored by a strain-gauge pneumograph positioned at the
id-chest level. Postganglionic efferent sympathetic nerve tischarge, heart rate, respiratory
ate, and skin blood flow were
ecorded continuously with a
ulti-channel digital data re-
order (MacLab/8S ML780, AD
nstruments Inc., Colorado
prings, Colorado). The level of
lertness in subjects was moni-
ored with the Observer’s Assess-
ent of Alertness/Sedation
OAAS) scale. The OAAS com-
rises 4 scales that researchers
se to assess alertness or seda-
ion: speech, responsiveness, fa-
ial expression, and eyes. A com-
osite score is determined by
umming the scores of all 4
cales; score of 5 correlates with
aximum alertness, and 1 indi-
ates deep sleep (13).
easurement of skin SNA. Multiunit recordings of post-
anglionic sympathetic nerve discharge were obtained with
nipolar tungsten microelectrodes inserted selectively into
kin nerve fascicles of the peroneal nerve posterior to the
bular head, according to the technique of Valbo (14). The
eural signals were amplified 20,000 to 50,000 times,
ltered (bandwidth 700 to 2,000 Hz), rectified, and inte-
rated (time constant, 0.1 s) with a nerve traffic analyzer
Bioengineering Department, University of Iowa) to obtain
mean voltage display of sympathetic discharge. A record-
ng of skin sympathetic nerve discharge was considered
cceptable when: 1) weak electrical stimulation (0.5 to 3.2 V,
.2 s, 1 Hz) through the electrode elicited paresthesias
ithout muscle contraction; 2) tactile stimuli within the
eceptive field of the impaled nerve fascicle elicited afferent
echanoreceptive impulses, whereas no impulses could be
voked by muscle stretch or contraction; and 3) the mean
oltage neurogram revealed bursts of neural activity (with a
ignal-to-noise ratio of 3:1) that increased during arousal
timuli (loud noise, skin pinch) but not during the Valsalva
aneuver. The intraobserver variabilities in identifying
ursts of skin SNA is 3.4% (range 0% to 11%), as previously
eported (3). All the records were analyzed by the same
nvestigator who scored the recorded data in a blinded
ashion. Inadvertent contraction of the leg muscles adjacent
o the recording electrode produces electromyographic arti-
acts that are easily distinguished from sympathetic bursts;
eurograms that revealed such artifacts were excluded from
nalysis. Nerve traffic was expressed as both bursts/minute
nd total integrated activity/min, which is the sum of the
ntegrated area under all the bursts detected in 1 min.
ntegration was performed with MacLab software.
easurement of skin blood flow. Skin blood flow was
easured by laser Doppler velocimetry (Advance Laser
lowmeter, ALF 2100, Advance Co., Tokyo, Japan) with
Abbreviations
and Acronyms
2 AR  alpha 2
adrenergic receptor
2CDel322-325  deletion
322-325 polymorphism of
the alpha 2C AR
DNA  deoxyribonucleic
acid
MAP  mean arterial
pressure
NE  norepinephrine
OAAS  observer’s
assessment of alertness/
sedation scale
PCR  polymerase chain
reaction
SNA  sympathetic nerve
activityhe probe placed on the plantar aspect of the first toe. Skin
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Cocaine and Dexmedetomidine August 14, 2007:626–33ascular resistance (expressed in resistance units) was calcu-
ated as the quotient of mean arterial pressure (MAP) and
kin blood flow (expressed in perfusion units). The SNA
nd vascular resistance were studied in the same vascular bed
f the same limb. This allowed us to ask whether elimina-
ion of the cocaine-induced sympathetic activation would
ffectively reverse its end-organ effect—namely cutaneous
asoconstriction.
enotyping. Subjects carrying the 2CDel322-325 poly-
orphism were identified as previously described (15).
riefly, genomic deoxyribonucleic acid (DNA) was isolated
rom peripheral blood with the Puregene kit (Gentra
ystem, Minneapolis, Minnesota); oligonucleotides were
urchased from Integrated DNA Technologies (Coralville,
owa). All sequencing was performed with an ABI 3730
utomated DNA Sequencing instrument and Big Dye
ersion 3.1 dye terminator chemistry (Applied Biosystems,
oster City, California). The 12 base pair (bp) in-frame
eletion (Del322-325) allele of the 2C AR was identified by
ize fractionation assay. A DNA fragment spanning the
olymorphic region was polymerase chain reaction (PCR)-
mplified and fluorescence-labeled with a FAM-labeled sense
rimer 5=-FAM-GTCTACGCGCGCATCTACCGAGT-
GCCAAG-3= and unlabeled antisense primer 5=-CCCAT-
ACCACAGCCAGCACAAAGGTGAAG-3=.
Amplicon sizes were determined with an ABI 3100
utomated DNA sequencer without purification of the PCR
roduct. The results of the fragment analysis were verified
y directly sequencing PCR fragments amplified with un-
abeled primers.
From a random population sample of 1,458 blacks in the
allas Heart Study (16), 246 subjects were homozygous for
he mutant allele. Of these, we enrolled 7 subjects from a
ool of 128 subjects who met the following inclusion
riteria: normotensive, non-diabetic, non-pregnant, and no
istory of cocaine or other drug abuse.
xperimental protocol. We performed the same experi-
ental protocol in 2 groups of subjects. In group 1, all
ubjects were homozygous for the common 2C AR
llele. In group 2, all were homozygous for the Del322-
25 allele.
ffect of dexmedetomidine on skin SNA and cutaneous
asomotor responses to intranasal cocaine in subjects
ith common 2C AR alleles. After stable baseline data
ere obtained for 15 min, each subject received intranasal
ocaine hydrochloride, 2 mg/kg in a 10% nasal solution
19 experiments in 15 subjects). This dose of intranasal
ocaine is one-half the standard clinical dose for rhino-
aryngologic procedures (17) and has been shown previ-
usly to cause reproducible increases in skin SNA and
kin vascular resistance that last for 90 min (3). The
ocaine solution was delivered into each nostril via a
ropper over a period of 5 min. After completion of nasal
dministration of cocaine for 30 min, which is time to
eak effect of intranasal cocaine, subjects were random- Dzed to receive either a single bolus intravenous dose of
exmedetomidine (Abbott Laboratories, Abbott Park,
llinois; n  11) at the dose of 0.1 and 0.3 g/kg over 1
in or saline at the identical volume used during dexme-
etomidine administration (0.025 and 0.075 ml/kg over 1
in, n  8) with a time interval of 10 min between the
doses of the drugs. Heart rate, blood pressure, sympa-
hetic nerve discharge, and skin blood flow were recorded
ontinuously for 50 min. Subjects were monitored for the
evel of alertness with the OAAS after administration of
oth doses of the drugs.
ffects of dexmedetomidine in individuals with the 2C
R Del322-325 variant allele. We repeated the previously
escribed protocol in homozygous carriers of the
2CDel322-325 allele with the identical procedures except
hat the saline control was not repeated in this group (7
xperiments in 7 subjects).
tatistical analyses. The SAS/STAT software (SAS,
ary, North Carolina) version 9.1 was used for all analyses.
resented p values are based on tests of contrasts within a
ixed linear model of each response variable with fixed
reatment group  genotype  time effect and random
ubject effect. Treatment group had 2 levels: dexmedetomi-
ine and saline. Genotype had 2 levels: wild and variant
ith respect to 2CDel322-325. Time had 4 levels: base-
ine, after cocaine, after 1st treatment dose, and after second
reatment dose. The random subject effect allows for de-
endence among repeated measures on the same individual.
he intervention effects (treatment group differences in
econd dose treatment—cocaine) were also tested with
ank-sum tests to confirm the conclusions on the basis of
he mixed linear models. Because the distributions of skin
NA (% integrated activity) were skewed, the data were
nalyzed after a natural logarithmic transformation. Two-
ided p values 0.05 were considered to indicate statistical
ignificance.
esults
one of the subjects developed chest pain, electrocardio-
raphic evidence of ischemia, or arrhythmias or any other
omplications from this low dose of intranasal cocaine.
aseline Characteristics of Subjects Treatedith I travenous Dexmedetomidine or S line
Table 1 Baseline Characteristics of Subjects TreatedWith Intravenous Dexmedetomidine or Saline
Cocaine 
Dexmedetomidine
(n  11)
Cocaine  Saline
(n  8)
Age (yrs) 40 3.2 35 5
Male/female 4/7 3/5
White/black 4/7 1/7
Body mass index (kg/m2) 25 1.2 26 1.3
Heart rate (beats/min) 65 2 58 3
Mean arterial pressure (mm Hg) 91 2 87 5ata expressed as mean  SE.
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August 14, 2007:626–33 Cocaine and Dexmedetomidineffects of dexmedetomidine on skin sympathetic and
asoconstrictor responses. Baseline characteristics of
ubjects in the saline and dexmedetomidine group are
hown in Table 1. Mean arterial pressure and heart rate
ncreased significantly after intranasal cocaine adminis-
ration alone, and skin SNA increased to a value that was
pproximately 2-fold of the baseline (p  0.01 for both
epeated measures analysis of variance [ANOVA] and
onparametric rank sum test) (Fig. 1, Table 2). Intrave-
ous saline infusion had no effect on the cocaine-induced
ncrease in skin SNA, MAP, and heart rate, which
emained constant for the entire duration of the protocol
Figs. 1 and 2, Table 2). The cocaine-induced increase in
kin SNA was accompanied by a sustained decrease in
kin blood flow and increase in skin vascular resistance,
hich was also unaffected by intravenous saline admin-
stration (Fig. 2, Table 2). The magnitude and duration
f the increases in SNA, skin vascular resistance, heart
ate, and MAP during administration of intranasal co-
Baseline
Cocai
alone
Cocaine plus
tomidineDexmede
0.3 µg/kg
Cocaine plus
omidineDexmedet
0.1 µg/kg
ne
Baseline
Cocai
alone
Cocaine plus
saline 0.075 ml/kg
Cocaine plus
saline 0.025ml/kg
ne
10 sec
Figure 1 Original Recordings of Skin SNA
Intranasal cocaine evoked a rapid and sustained increase in skin sympathetic
nerve activity (SNA), which is reversed by dexmedetomidine (Dex), beginning at
the dose of 0.1 g/kg/min but not by intravenous saline. The SNA is in arbi-
trary units along the Y-axis.
Dose-Dependent Effects of Saline on Responses
Table 2 Dose-Dependent Effects of Saline o
Saline Group (n  8) Baseline
Mean arterial pressure (mm Hg) 87 5
Heart rate (beats/min) 58 3
Skin SNA
Integrated activity, % 100
Ln % integrate activity 4.61 0
Skin blood flow (perfusion units) 8.03 1.78
Skin vascular resistance
(resistance units)
13.24 2.30
OAAS scale 5 0Data expressed as mean  SE. *p  0.01 versus baseline; †p  0.05 versus
OAAS  observer’s assessment of alertness and sedation; SNA  sympathaine  intravenous saline were comparable to those
eported previously with intranasal cocaine alone (3,4),
uggesting that intravenous saline had no impact on
ympathetic and hemodynamic responses to cocaine.
In contrast, low dose of dexmedetomidine (0.1 g/kg/
in) abolished effects of cocaine on the skin SNA and
eturned SNA to baseline; whereas the higher dose of
exmedetomidine (0.3 g/kg/min) reduced SNA further
o 35% of baseline activity (p  0.01 for both repeated
easures ANOVA and nonparametric rank sum test)
Fig. 1, Table 3). Dexmedetomidine also reversed the
ocaine-induced increases in skin vascular resistance,
AP, and heart rate in a dose-dependent fashion, which
as not observed with saline (Fig. 2, Tables 2 and 3).
here were no changes in subjects’ alertness as evidenced
y OAAS scale with either dose of dexmedetomidine
Table 3).
tranasal Cocaine
ponses to Intranasal Cocaine
Cocaine
Plus Saline
0.025 ml/kg
Plus Saline
0.075 ml/kg
01 3* 98 3* 97 4*
76 3* 72 2* 71 3*
46 46 231 40 217 29
42 0.21* 5.38 0.19* 5.34 0.15†
24 0.59† 4.98 0.57† 4.71 0.53*
16 2.16* 20.69 2.16* 21.69 2.19*
5 0 5 0 5 0
L
n
?
%
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3
4
5
6
Baseline Cocaine
Skin SNA
†
*
+ Dex 0.
or Salin
‡
†
1
e
+ Dex 0.3
or Saline
§
†
†
R
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?
u
n
it
s
Skin Vascular Resistance
Dexmedetomidine (n=11)
Saline (n=8)
10
15
20
25
Baseline Cocain
†
†
e + Dex 0.
or Salin
*
†
1
e
+Dex 0.3
or Saline
†
§
Figure 2 Changes in Skin SNA and Skin Vascular
Resistance In Response to Cocaine and Dex
Intranasal cocaine increased skin sympathetic nerve activity (SNA), which was
accompanied by a parallel increase in skin vascular resistance. Dexmedetomi-
dine (Dex) reversed effects of cocaine on SNA and skin vascular resistance,
beginning at the dose of 0.1 g/kg/min. Data are mean  SE. *p  0.05 ver-
sus baseline, †p  0.01 versus baseline, ‡p  0.05 versus saline, §p 
0.01 versus saline.to In
n Res
1
2
5.
5.
20.baseline.
etic nerve activity.
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Cocaine and Dexmedetomidine August 14, 2007:626–33ffectiveness of dexmedetomidine on responses to co-
aine in the presence of the 2CDel322-325 polymor-
hism. Table 4 presents the baseline characteristics of
ubjects homozygous for 2CDel322-325 allele and com-
ares with those of 11 subjects with common allele, which
re the same subjects who received cocaine  dexmedeto-
idine in Table 1. Table 5 presents the responses to cocaine
lone and in combination with dexmedetomidine in the
omozygous carriers, whereas Table 3 presents the compa-
able data for the control subjects carrying only the common
llele. The responses to cocaine and the effects of dexme-
etomidine on these responses were similar in the 2 groups,
ith no evidence of attenuated dexmedetomidine action in
he subjects homozygous for the mutant allele (Tables 3 and
, Fig. 3). The OAAS was also unaffected by dexmedeto-
idine in this group of subjects as well.
iscussion
he major new findings of this study are 2-fold. First, the
entrally acting 2 agonist dexmedetomidine was effective
nd safe in abolishing both the sympathoexcitatory and
orresponding hemodynamic effects of cocaine in healthy
ocaine-naïve human subjects. Second, the 2-agonist re-
ained equally effective in subjects homozygous for a
oss-of-function mutation in the 2C AR (Del322-325)
resent in the majority of blacks, suggesting the importance
ose-Dependent Effects of Dexmedetomidine on Responses to Intr
Table 3 Dose-Dependent Effects of Dexmedetomidine on Respo
Dexmedetomidine Group
(n  11) Baseline Cocaine
Mean arterial pressure (mm Hg) 91 2 100 2†
Heart rate (beats/min) 65 2 77 2†
Skin SNA
Integrated activity, % 100 174 10
Ln % integrate activity 4.61 0 5.15 0.0
Skin blood flow (perfusion units) 6.03 0.56 4.83 0.5
Skin vascular resistance
(resistance units)
16.20 1.38 22.26 1.7
OAAS scale 5 0 5 0
ata expressed as mean  SE. *Interaction between treatment group and time effect and represe
ocaine; §p  0.01 versus saline; p  0.05 versus baseline; ¶p  0.05 versus cocaine; #p  0.0
NS  non-significance at the level of p  0.05; OAAS  observer’s assessment of alertness an
aseline Characteristics of Subjects With the2CDel322-325 Variant of the 2C Adrenergicec ptor Allele
Table 4
Baseline Characteristics of Subjects With the
2CDel322-325 Variant of the 2C Adrenergic
Receptor Allele
Common 2C
Allele (n  11)
2CDel322-325
Allele (n  7)
Age (yrs) 40 3.2 44 1.8
Male/female 4/7 3/4
White/black 4/7 1/6
Body mass index (kg/m2) 25 1.2 28 3.3
Heart rate (beats/min) 65 2 69 5
Mean arterial pressure (mm Hg) 91 2 93 3a
ata expressed as mean  SE. p value of all variables 0.05 common 2C versus 2CDel322–
25 allele.f other 2 AR subtypes and the applicability of the study
esults to a diverse multi-ethnic population.
ffectiveness and safety of dexmedetomidine as a counter-
easure to the sympathomimetic actions of cocaine.
lthough cocaine is well known to block NE reuptake in
eripheral sympathetic nerve terminals in experimental
reparations, in conscious humans cocaine’s sympathomi-
etic effects on the heart and peripheral circulation seem to
e caused primarily by central activation of SNA (3,4). The
atter central mechanism of cocaine action provided the
ationale for implicating central sympatholytic drugs as a
otential new countermeasure, the effectiveness of which
reviously has been demonstrated only in experimental
nimals. In anesthetized rats, clonidine has been shown to
everse the pressor response to cocaine (5). In dogs, dexme-
etomidine—a central sympatholytic agent with 8-times-
igher binding affinity for 2 ARs than clonidine (6,7)—
eversed cocaine-induced vasoconstriction in both the
eripheral and coronary circulations (10).
The cutaneous circulation provided an excellent oppor-
unity to extend these mechanistic observations to conscious
umans. We previously showed that even a small sub-
uphoric dose of intranasal cocaine produces large increases
n both skin SNA and skin vascular resistance that last for at
east 90 min (3). Thus, this experimental approach provided
stable, centrally generated vasomotor response to examine
ts modulation by a central sympatholytic drug such as
exmedetomidine. In humans, skin SNA is highly reactive
o central neural influences such as cocaine but unreactive to
hanges in baroreceptor activity, which would otherwise
omplicate the interpretation of centrally mediated re-
ponses (18,19). Under normothermic conditions, cocaine-
nduced increases in skin SNA are vasoconstrictor impulses.
hus, the combination of microneurographic and laser
oppler techniques allowed us to study SNA and its
ownstream vasoconstrictor effect in the same human vas-
ular bed.
Dexmedetomidine allowed us to readily control and
ompletely eliminate the SNA response to cocaine. This is
l Cocaine
to Intranasal Cocaine
Plus
Dexmedetomidine
0.1 /kg
Plus
Dexmedetomidine
0.3 /kg p Value*
93 3‡§ 89 2‡§ 0.01
76 2† 68 2‡§ NS
103 11 35 8
4.0 0.11#¶ 3.37 0.28†‡§ 106
6.87 2.34 8.50 2.22#§ NS
19.58 2.2 15.10 2.24‡§ 0.001
5 0 5 0 NS
erence in response between dexmedetomidine and saline; †p  0.01 vs. baseline; ‡p  0.01 vs.
s saline.
ion; SNA  sympathetic nerve activity.anasa
nses
6
0
8†
nts diffpotent effect, because it occurred with doses of dexme-
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August 14, 2007:626–33 Cocaine and Dexmedetomidineetomidine that are only 20% to 30% of the loading doses
ypically used to produce anesthesia and had no detectable
ffect on levels of consciousness in any of our experiments.
hen we eliminated the cocaine-induced increase in skin
NA with dexmedetomidine, the corresponding cutaneous
asoconstrictor response also was eliminated. This is an
mportant observation, because 2 AR agonists can some-
imes cause vasoconstriction by acting directly on arteriolar
ost-junctional 2 ARs, (13) which would have been
etrimental in the setting of cocaine. However, we found no
vidence for such an effect in our experiments.
Furthermore, we found no evidence that dexmedeto-
idine was any less effective in homozygous carriers of
he 2CDel322-325 allele, even though the allele has
een reported to encode a less active 2C AR (20) and to
e associated with elevated NE spillover (in healthy
umans) (21) and a 10-fold increased risk of heart failure.
11) Because dexmedetomidine activates all 3 subtypes of
L
n
%
 T
o
ta
l  
n
er
ve
 a
ct
iv
it
y
Skin SNA
Baseline Cocaine Plus
Dex 0.1
Plus
Dex 0.3
5
15
25
 R
es
is
ta
n
ce
 u
n
it
s 
2.5
4.5
6.5
Baseline Cocaine
†
*
Plus
Dex 0.1
Plus
Dex 0.3
*
†
Skin Vascular Resistance
Common α 2C allele (n=11)
α 2C Del322-325 allele (n=7)
†
†
*
Figure 3 Changes in Skin SNA and Vascular Resistance
in Subjects With 2CDel322-325 Allele
Intranasal cocaine caused a similar increase in skin sympathetic nerve activity
(SNA) and skin vascular resistance in both groups of subjects. Dexmedetomi-
dine (Dex) reversed effects of cocaine on SNA and skin vascular resistance
similarly in both groups. Data are mean  SE. *p  0.05 versus baseline,
†p  0.01 versus baseline.
ose-Dependent Effects of Dexmedetomidine in Subjects With the
Table 5 Dose-Dependent Effects of Dexmedetomidine in Subjec
2CDel322-325 Variant Allele (n  7) Baseline Co
Mean arterial pressure (mm Hg) 93 3 101
Heart rate (beats/min) 69 5 79
Skin SNA
Integrated activity, % 100 416
Ln % integrate activity 4.61 0 5.62
Skin blood flow (perfusion units) 9.41 2.05 8.66
Skin vascular resistance (resistance units) 12.68 2.30 17.88
OAAS scale 5 0 5
ata expressed as mean  SE. *Interaction between genotype and time effect and represents dif
0.01 versus baseline; ‡p  0.01 versus cocaine; §p  0.05 versus baseline.
NS  non-significance at the level of p  0.05; OAAS  observer’s assessment of alertness ans2fARs, 2A and 2B as well as 2C, the present
ndings are consistent with mouse studies indicating
onsiderable redundancy in the effects of the three
eceptor subtypes in cardiovascular regulation (22–24).
ur findings also are consistent with more recent clinical
tudies indicating that this polymorphism, although
ighly enriched in blacks, is not as important functionally as
nitially thought. In patients with heart failure, no association
as found between the 2CDel322-325 allele and elevated
ardiac NE spillover (25). In a large multiethnic population
ample, no association was found between this allele and
ypertension or hypertensive heart disease (15). For these
easons, dexmedetomidine is likely to be an effective counter-
easure for cocaine’s sympathomimetic effects in ethnically
iverse populations.
tudy limitations. Despite the strengths of the study, there
re several factors that limit the clinical applicability of the
resent findings. First, for obvious ethical reasons, the
ocaine dose used in these studies was small, requiring only
ow doses of dexmedetomidine. Further clinical trials are
eeded to determine the efficacy and safety of larger doses of
exmedetomidine in counteracting the cardiovascular effects
f higher recreational doses of cocaine. However, even very
arge doses of dexmedetomidine—10 times higher than that
pproved for anesthesia—are well-tolerated without causing
espiratory depression (13), an advantage over the sedatives
urrently used to treat cocaine intoxication (i.e., morphine,
enzodiazepines). Second, because we studied healthy
ocaine-naïve subjects, the results cannot be extrapolated to
hronic cocaine abusers. However, in isolated case reports
exmedetomidine has been effective in reducing agitation,
achycardia, and hypertension in poly-substance abusers
ndergoing withdrawal from cocaine, alcohol, and opiates
26,27). Third, here we focused on the human cutaneous
irculation and skin sympathetic activity. Additional studies
re needed to determine whether dexmedetomidine is
qually effective in the human coronary circulation and
ardiac sympathetic activity as well as other regional sym-
athetic outflow. Interestingly, a recent meta-analysis
el322-325 Variant Allele
ith the 2CDel322-325 Variant Allele
Plus
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0.1 /kg
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0.3 /kg p Value*
95 3‡ 89 2‡ NS
78 † 72 ‡ NS
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5 0 5 0 NS
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igh-risk patients (28).
linical implications and conclusions. The present data
rovide a conceptual framework for suggesting a new use for
n old class of cardiovascular drugs—central sympatholytics
s a novel countermeasure for the acute cardiovascular
omplications of cocaine. Currently, nitrates are considered
rst-line therapy (Class I indication) for cocaine-associated
cute coronary syndrome (29); however, they can worsen
yocardial oxygen demands by causing reflex tachycardia
30,31). Benzodiazepines (Class IIa indication) and mor-
hine might help to reverse cocaine-induced coronary isch-
mia as well as agitation (31,32), but they are ineffective
gainst cocaine-induced acute hypertension and tachycardia
31,33) and can cause respiratory depression. Beta blocker
rugs are generally contraindicated in the setting of cocaine
ntoxication to avoid unopposed 1 adrenergic coronary
asoconstriction. Labetalol, a combined -/beta-blocker,
ight attenuate cocaine-induced acute hypertension but
nfortunately is not effective in reversing cocaine-induced
oronary vasoconstriction (34). Calcium channel blockers
uch as verapamil are effective in reversing cocaine-induced
oronary vasoconstriction but not in reversing effects of
ocaine on the heart rate (35). In contrast, by eliminating
ocaine’s multiple sympathomimetic actions at their origin,
exmedetomidine might constitute effective monotherapy
or this common clinical problem by providing a controlled
eduction in blood pressure and heart rate and reversing
eripheral vasoconstriction.
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